Faster to market, with less friction for the practitioners and admin staff behind every trial.
Drug developers use Weva's deidentified real-world data to define the ideal patient phenotype for a trial and locate exactly where it exists. Weva then alerts both the treating practitioners and the phenotype-matched patients to encourage uptake, cutting the time and cost of recruitment dramatically.
Recruitment is where trials stall and budgets blow out. Many trials miss their enrolment timelines because the ideal phenotype is a guess, and even when it's known, reaching the right patients at scale is slow and expensive. Weva fixes both.
Sponsors interrogate Weva's de-identified real-world data to build the ideal patient phenotype, the precise clinical profile most likely to be eligible, respond and complete.
Weva maps where that phenotype concentrates: the practitioners, sites and populations already caring for the patients your trial needs.
Weva sends targeted alerts to both practitioners and their phenotype-matched patients, putting the trial in front of exactly the right people and driving enrolment, saving months of recruitment time and significant cost.
With the right patients identified and engaged from the start, sponsors close higher-quality trials in less time and more patients reach the therapies they're entitled to, sooner.
Recruit faster by starting with the ideal phenotype instead of finding it the hard way. Screen-fail less because phenotype-matched patients mean fewer wrong-fit candidates through the door. Spend less with fewer sites, less broad advertising, and shorter timelines.
Weva serves the entire clinical trials ecosystem
01
Design smarter protocols using phenotypes to improve recruitment quality with potential for real-time global digital trial registries.
02
Bring phenotype-led recruitment intelligence that wins studies and delivers them on time.
02
Can engage in Clinical Trials when they previously couldn't with improved uptake and less administrative burden.
02
Have greater health literacy and streamlined access to therapies that they are entitled to.
Result: #1 global recruiter in the cohort
Result: #1 global recruiter in the cohort. Nightingale Research Adelaide used Weva digital phenotypes to recruit 84 patients within a short period of time for a clinical trial in early 2026, becoming the number one global recruiter in that cohort.
.svg)
.svg)